Narative Review: Kejadian Dan Mekanisme Kardiotoksisitas Pada Pasien Kanker Payudara Setelah Penggunaan Trastuzumab

Laras Ratna Sari; Retno Murwanti; Fita Rahmawati

doi:10.22146/farmaseutik.v20i3.97047

Narative Review: Kejadian Dan Mekanisme Kardiotoksisitas Pada Pasien Kanker Payudara Setelah Penggunaan Trastuzumab

https://doi.org/10.22146/farmaseutik.v20i3.97047

Laras Ratna Sari⁽¹⁾, Retno Murwanti^(2*), Fita Rahmawati⁽³⁾

(1) Program Pascasarjana Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta
(2) Departemen Farmakologi Dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Farmakologi Dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Kardiotoksisitas adalah terjadinya disfungsi jantung sebagai kerusakan listrik atau otot, yang mengakibatkan jantung menjadi lebih lemah dan tidak efisien dalam memompa darah. Kardiotoksisitas dapat disebabkan oleh beberapa hal seperti agen kemoterapi, pengobatan radioterapi, komplikasi dari anoreksia nervosa, efek samping dari asupan logam berat. Kardiotoksisitas juga terjadi pada pasien kanker payudara yang diberikan terapi trastuzumab. Tujuan dari tinjauan artikel ini yaitu untuk mengetahui kejadian kardiotoksisitas setelah penggunaan trastuzumab dan mekanisme efek kardiotoksisitas trastuzumab pada pasien kanker payudara. Metode yang digunakan pada artikel ini yaitu menggunakan beberapa pencarian menggunakan PubMed, ScienceDirect dan Google Cendekia untuk penelitian yang membahas efek kardiotoksisitas trastuzumab pada pasien kanker payudara dari tahun 2018 sampai dengan 2023. Dari total 171 artikel, yang kemudian dievaluasi berdasarkan kriteria inklusi dan eksklusi. Sebanyak 157 artikel dikeluarkan dan 14 artikel yang memenuhi kriteria inklusi. Mekanisme terjadinya kardiotoksisitas oleh trastuzumab melalui mekanime penghambatan HER2 dan autophagy. Kesimpulannya, Pemilihan trastuzumab sebagai pilihan terapi pada pasien kanker payudara harus dipertimbangkan dengan cermat dan diperlukan pemantauan fungsi jantung.

Keywords

kardiotoksisitas; trastuzumab; kanker payudara

Full Text:

PDF

References

Alghafar, A. Doaa, Ibrahim, Younos.,, Khalid, A. Baimani., Dawood, Al-Salhi., Adil, Al-Riyami., Syed, Rizvi., and Niamh, E. Buckley., 2020, Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman, J Oncol Pharm Practice 0(0) 1–10, DOI: 10.1177/1078155220919888

Banke, Ann, MD, Emil, L. Fosbol, MD, PHD, Marianne, E., PROFESSOR, MD, DMSC,, Lars, V.,, MD, PH D, Jordi, S. Dahl, MD, PHD, Mikael K. Poulsen, MD, PHD, Cold, MD, P HD, Maj-Britt, J., ANDSCIENT, Gunnar, H. Gislason, MD, P HD, Morten, S., MD, P HD, Jacob, E., MD, DMS CI, 2019, Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab, JACC: HEARTFAILURE VOL.7, NO. 3,201 9, doi.org/10.1016/j.jchf.2018.09.001

Bergamini, Corinna., Giulia, Dolci., Andrea, Rossi., Flavia, Torelli., Luca, Ghiselli., Laura, Trevisani1., Giulia, Vinco., Stella Truong., Francesca, La Russa, Giorgio, Golia., Annamaria Molino, Giovanni, Benfari., Flavio, Luciano., 2018, Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity, Clinical Cardiology. 2018;41:349–353, DOI: 10.1002/clc.22872

Chang, Wei-Ting, Chen, Po-Wei, Lin, Hui-Wen, Lin, Sheng-Hsiang and Li, Yi-Heng, 2021, Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan, ESC Heart Failure 2021; 8: 5149–5158 DOI: 10.1002/ehf2.13591

Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443–446 10.1038/74704

Dipiro, J., Talbert, L.R., Yee, G.C., Matzke, G R., Wella, B.G., Possey, L., 2008, Pharmacotherapy A Pathophysiologic Approach, 7^th Edition, Micc Grow Hill Medical, Washington Dc, 1026-1226

Eaton, H., and Timm N. Kerstin, 2023, Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?, . Cardio-Oncology (2023) 9:22 https://doi.org/10.1186/s40959-023-00172-3

Eiger, Daniel., Maria, A. Franzoi., Noam, P., Mariana, B., Claudia de A.,Melanie S. Nogueira, Quentin, de H., Evandro, de A., 2019, Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials, ESMO Open 2020;5:e000659. doi:10.1136/esmoopen-2019-000659

Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. (2015) 22:377-88. 10.1038/cdd.2014.150

Globacan, 2020, global cancer observatory, https://gco.iarc.fr/en

Henry, L. Mariana BS,a Jiangong Niu, PHD, a Ning Zhang, MS, a Sharon H. Giordano, MD, MPH,a,b, Mariana Chavez-MacGregor, MD, MS, 2018, Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients, jack : cardiovascular imaging, vol.11, no.8,2018, https://doi.org/10.1016/j.jcmg.2018.06.005

Huang, C., Zhang, X., Ramil, J. M., Rikka, S., Kim, L., Lee, Y., Gude, N. A., Thistlethwaite, P. A., Sussman, M. A., 2010, Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice, Circulation. 121 (5):675–83.
doi:10.1161/CIRCULATIONAHA.109.902221. PMC 2834271. PMID 20100968

Hudis, C. A. (2007). Trastuzumab — Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine, 357(1), 39–51. doi:10.1056/nejmra043186

Klapper L. N., Waterman H., Sela M., Yarden Y. (2000). Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60, 3384–3388

Lin, Mengmeng., Weiping Xiong, Shiyuan Wang, Yingying Li , Chunying Hou , Chunyu Li and Guohui Li, 2022, The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment, Front. Cardiovasc. Med., Volume 8 – 2021

Litvak, Anya MD, Bhavina Batukbhai, MD., Stuart D. Russell, MD., Hua-Ling Tsai, ScM3, Gary L. Rosner, ScD, Stacie C. Jeter, CCRP, Deborah Armstrong, MD, Leisha A. Emens, MD, PhD, John Fetting, MD, Antonio C. Wolff, MD, Raquel Silhy, MD, Vered Stearns, MD, and Roisin M. Connolly, MD, 2018, Racial Disparities in the Rate of Cardiotoxicity of HER2-Targeted Therapies Among Women With Early Breast Cancer, Cancer, DOI: 10.1002/cncr.31260

Liu, Peipei, Jiajun, Fan., Ziyu, Wang., Wenjing, Zai., Ping, Song, Yongping, Li., Dianwen, Ju.,2020, The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells, AMB Express . 2020 Jun 3;10(1):107. doi: 10.1186/s13568-020-01044-0.

Mohan, Nishant ; Jiang, Jiangsong; Milos, Dokmanovic and Wen, J. Wu., 2018, Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers, Antibody Therapeutics, 2018, Vol. 1, No. 1 13–17 doi:10.1093/abt/tby003

Moilanen, Tiina., Anna, J., Olli, T., Jussi, P. Koivunen, 2018, Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients, Journal of Cancer Research and Clinical Oncology, doi.org/10.1007/s00432-018-2682-9

NCCN, 2020, NCCN Guideline For Patient: Breast Cancer, NCCN.org/patient

Olorundare, O. Esan, Adejuwon, A. Adeneye, Akinyele, O. Akinsola, Abayomi, M. Ajay, Olalekan, A. Agede, Sunday, S. Soyemi, Alban, I. Mgbehoma, Ikechukwu, I. Okoye, Ralph, M. Albrecht, James, M. Ntambi, Peter, A. Crooks, 2021, Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity, Front Pharmacol, doi: 10.3389/fphar.2020.610331. eCollection 2020

Saleh, K. A., Abdel‑Warith, Ahmed., Alghamdi Abdurrahman, Mohammed., Aldiab, A., Ali, E., Fawzi, A. Waleed., Nabeel, A., 2022, Incidence of trastuzumab‑induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center, Molecular and Clinical Oncology, doi.org/10.3892/mco.2022.2511

Siahaan, I.H., Tobing, T.C., Rosdiana, N. dan Lubis, B. (2007). Dampak kardiotoksik obat kemoterapi golongan antrasiklin. Sari Pediatri 9 (2): 151-156.

Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al.. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure, Genes Dev, 2013, doi: 27:1365-77. 10.1101/gad.215871.113

Zhang, Li., Yan, Wang., Wenjing, Meng., Weipeng, Zhao., & Zhongsheng, Tong.,2022,Cardiac safety analysis of anti‑HER2‑targeted therapy in early breast cancer, Scientific Reports (2022) 12:14312 doi.org/10.1038/s41598-022-18342-1

Zhou, Shijie., Filipe, Cirne., Chow, Justin., Arman, Zereshkian., Louise, Bordeleau., Sukhbinder, Dhesy-Thind., Peter, M. Ellis., Som D. Mukherjee., Nazanin, Aghel., Darryl, P. Leong., 2023, Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab, The Oncologist, 2023, 28, e712–e722 doi.org/10.1093/oncolo/oyad086

DOI: https://doi.org/10.22146/farmaseutik.v20i3.97047